Therefore, this study reveals a novel mechanism by which MUC1‐PP2A awakes CSLC expansion via switching symmetric division, suggesting a potential therapeutic strategy for MUC1‐positive SCLC. Here, MUC1 is linked to small cell lung carcinoma.